Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

2006

Comparison of MRI and Symptom Outcomes of
Uterine Artery Embolization for Uterine
Leiomyomata Using Tris-Acryl Gelatin
Microspheres, Poly-Vinyl Alcohol Spheres and
Poly-Vinyl Alcohol Particles.
Jorge Augusto Gálvez Delgado
Yale University

Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Part of the Medicine and Health Sciences Commons
Recommended Citation
Gálvez Delgado, Jorge Augusto, "Comparison of MRI and Symptom Outcomes of Uterine Artery Embolization for Uterine
Leiomyomata Using Tris-Acryl Gelatin Microspheres, Poly-Vinyl Alcohol Spheres and Poly-Vinyl Alcohol Particles." (2006). Yale
Medicine Thesis Digital Library. 238.
http://elischolar.library.yale.edu/ymtdl/238

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

COMPARISON OF MRI AND SYMPTOM OUTCOMES OF UTERINE ARTERY
EMBOLIZATION FOR UTERINE LEIOMYOMATA USING TRIS-ACRYL
GELATIN MICROSPHERES, POLY-VINYL ALCOHOL SPHERES AND POLYVINYL ALCOHOL PARTICLES.

A Thesis Submitted to the
Yale University School of Medicine
In Partial Fulfillment of the Requirements for the
Degree of Doctor of Medicine

by
Jorge Augusto Gálvez Delgado
2006

COMPARISON OF MRI AND SYMPTOM OUTCOMES OF UTERINE ARTERY
EMBOLIZATION FOR UTERINE LEIOMYOMATA USING TRIS-ACRYL
GELATIN MICROSPHERES, POLY-VINYL ALCOHOL SPHERES AND POLYVINYL ALCOHOL PARTICLES.
Jorge A. Gálvez, Shirley M. McCarthy, Jeffrey Pollak, Jeffrey Weinreb, Daniel
Zelterman, Robert White and Michael G. Tal. Section of Vascular and Interventional
Radiology, Department of Diagnostic Radiology, and Department of Epidemiology and
Public Health, Yale University School of Medicine, New Haven, CT.
Abstract
Purpose: To compare the recurrence rate of symptoms and MRI enhancement of uterine
fibroids in patients treated with uterine artery embolization (UAE) among three embolic
agents: polyvinyl alcohol (PVA) particles, spherical polyvinyl alcohol (SPVA) particles
and tris-acryl gelatin microspheres (GM).
Materials & Methods: Women treated with UAE for fibroids with PVA, SPVA or GM
were contacted by telephone/ mail to complete a modified Uterine Fibroid Symptom
Quality of Life (UFS-QOL) survey. Baseline and post-UAE gadolinium-enhanced
magnetic resonance imaging (MRI) studies were evaluated for residual or persistent
enhancement of any uterine fibroids after UAE. Data was analyzed using 2-tail fisher’s
exact test to correlate symptoms and enhancement and determine the liklihood of
recurrence of enhancement and symptoms following UAE among three embolic agents.
Results: A total of 101 women underwent UAE with one of the three embolic agents and
had complete pre- and post-embolization MRI follow-up. In this group, a total of 24 of
59 (41%) women in the PVA group, 18 of 24 (75%) women in the SPVA group, and 4 of
18 (22%) women in the GM group showed residual enhancement in some or all fibroids.
Statistically significant differences in recurrence of residual enhancement on follow-up
MR imaging were found between SPVA and PVA (p=0.0072), as well as SPVA and GM
(p=0.0015), but not between PVA and GM (p=0.1756). No statistically significant
correlation between residual enhancement and symptom recurrence was found based on
the survey responses.
Conclusion: Patients embolized with SPVA have a higher risk of having residual
enhancement on follow-up MR imaging than those embolized with PVA or GM.
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Introduction
Uterine fibroids are the most common benign tumor of the female reproductive
tract, affecting 20-77% of the population (1). These benign tumors take a significant toll
on the US health care system, accounting for over 1 billion dollars of US health care
expenditures per year, as well as approximately 900,000 hospital days per year (2).
Roughly thirty-five to fifty percent of women with fibroids suffer from a constellation of
symptoms including menorrhagia, dyspareunia, dysmenorrhagia, reproductive difficulties
such as infertility or miscarriage, as well as pressure-related symptoms such as urinary
frequency or urgency, bloating, and constipation (3). The tumors typically arise during
perimenopausal years and regress during menopause. The diagnosis of uterine fibroids is
typically made by history and physical examination and can be confirmed with either
pelvic ultrasound or magnetic resonance imaging with or without gadolinium contrast.

Treatment Options
There are several options available for management of fibroid-related symptoms
including hysterectomy and myomectomy, though more recently techniques such as
transvaginal resection of fibroids (4), laparoscopic-directed thermal coagulation (5),
endometrial ablation (6), laser coagulation (7), cryotherapy (8) and MR-guided focused
ultrasound surgery (9). Hysterectomy is the most commonly prescribed surgical option
for women with symptomatic fibroids, with an estimated 177-366,000 women
undergoing hysterectomies annually for this indication (2). Myomectomy is the second
most common treatment, with an estimated 37-45,000 women undergoing myomectomies
each year (2).
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Typically, women often seek non-surgical alternatives for treatment of fibroidrelated symptoms. Medical therapies include GnRH analogs (10), gestrinone, (11) and
low-dose mifepristone (12). However, these alternatives are not successful in all
candidates, and quite often women experience recurrence of symptoms upon
discontinuation of the medication (13). As a result, therapies such as Uterine Artery
Embolization (UAE), which was first described by Ravina et al. in 1995 (14) but used
previously for treatment of intractable post-partum hemorrhage (15), have been growing
in popularity.
The rates of clinical success of these procedures – defined as complete resolution
of fibroid-related symptoms requiring no additional treatment – are comparable. UAE is
typically quoted at approximately 90%, myomectomy at 80% and hysterectomy at 100%
(2). Hysterectomy is a major surgical procedure, involving several days of
hospitalization followed by four to six weeks of recovery resulting in permanent loss of
uterus. While myomectomy preserves the uterus, it is still a major operation with similar
recovery times as hysterectomy. In contrast, UAE requires a relatively short hospital
stay, typically one day or less, and 1-2 weeks of recovery (16). According to the
American College of Obstetricians and Gynecologists’ (ACOG), the overall morbidity
for UAE is reported to be 5%, as opposed to that of myomectomy at 38.6% and
hysterectomy at 40.1% (17). Although UAE preserves the uterus while providing relief
of fibroid related symptoms, the ACOG regards it as an investigational or relatively
contraindicated procedure in women wishing to retain fertility (18). However, Ornan et al
(19) studied the long-term sequelae of uterine artery embolization for intractable postpartum hemorrhage and found that all patients who desired to get pregnant were able to
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do so, and experienced uncomplicated deliveries years after the embolization.
Nevertheless, gynecologists are increasingly recommending UAE to their patients as a
treatment alternative for symptomatic fibroids (20).
Recurrence rates after UAE are estimated around 10% after 2 years (21). While
some studies have shown that some patients may require further invasive treatment 3-5
years after the procedure, the satisfaction level with the procedure remains high among
the women who choose to undergo UAE (22). In a large multicenter trial comparing 100
patients undergoing UAE with 50 patients undergoing hysterectomy for symptom
improvement after 12 months showed that both procedures had comparable results with
an advantage for hysterectomy on pelvic pain, yet complications were infrequent in both
procedures (23).

Embolic Agents used in Uterine Artery Embolization for Uterine Leiomyomata
Despite the large number of studies evaluating the procedure (24-29) and the
individual embolic agents commercially available (28, 30-35), there have been few
studies comparing the MRI enhancement and clinical outcomes among different embolic
agents (36, 37). Among the first agents used for UAE to treat fibroids were poly-vinyl
alcohol particles (PVA) and gelfoam (38). Gelfoam was traditionally used when
embolizing the female reproductive organs because it caused only a temporary occlusion
of the targeted vasculature (38). Before UAE for fibroids, PVA was not routinely used
for pelvic embolization procedures in women (38).
The introduction of tris-acryl gelatin microspheres (GM; Embosphere
Microspheres; Biosphere Medical, Rockland, MA) provided the first spherical embolic
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agent for UAE. As this new agent was introduced to practice, a modified technique for
UAE was developed which consisted of a limited embolization endpoint with similar
results as the previous agents being used (32). The introduction of spherical PVA
(SPVA) particles (Contour SE; Boston Scientific) provided yet another spherical embolic
agent, which received approval from the Food and Drug Administration for the specific
indication of treatment of uterine fibroid tumors in 2004. This embolic agent was
available in the same size categories as the GM, and was considered to have similar
performance characteristics as GM.
There is little evidence in the literature comparing clinical outcomes among
different embolic agents. A randomized prospective trial compared the original PVA
with GM which demonstrated that both embolic agents had similar efficacy as measured
by short-term clinical outcome and imaging follow-up (36). Recently, a prospective
randomized trial comparing GM and SPVA was conducted to evaluate clinical outcome
and MR imaging outcome at 3 months after the UAE (37). This study was terminated
before patient enrollment was completed because SPVA was found to have worse
symptom outcome as measured with the Uterine Fibroid Symptom – Quality of Life
questionnaire (UFS-QOL) and more likely to have incomplete infarction of uterine
leiomyomata as seen on contrast-enhanced MR imaging (37).

Diagnostic Imaging Follow-Up
There are two general modalities for imaging of the female pelvis which allow
visualization of uterine fibroids: pelvic or transvaginal ultrasound and magnetic
resonance imaging (MRI). While both transvaginal ultrasonography and MRI are
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accurate at detecting uterine fibroids (39), ultrasound is limited because it does not allow
for assessment of fibroid perfusion, and does not permit the large field of views
obtainable with MRI for accurate volume assessment (40). Contrast-enhanced MR
imaging allows for visualization of perfused areas of myometrium and fibroid tissue,
which can be used to monitor response to UAE treatment (41, 42). The goal of UAE is to
cause complete infarction of all fibroids while maintaining perfusion of the myometrium
(43). Residual enhancement of uterine fibroids has been associated with an increased risk
for recurrence of fibroid-related symptoms within the first two years after UAE (42). As
such, it is necessary to employ imaging modalities that can distinguish fully infarcted
fibroids from incompletely infarcted ones to be used when designing studies that evaluate
clinical outcomes of uterine artery embolization (37).
Therefore, the aim of this research is to retrospectively compare the enhancement
of fibroids at 6-month gadolinium-enhanced MRI studies with prospective recurrence of
symptoms and in patients treated with UAE with the three aforementioned embolic
agents; poly-vinyl alcohol particles (PVA), poly-vinyl alcohol spheres (SPVA) and trisacryl gelatin microspheres (GM).
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Statement of Purpose
The purpose of this study was to compare the clinical outcomes among three
commercially available embolic agents used for uterine artery embolization for uterine
leiomyomas. Our hypothesis is that there are differences in the clinical outcomes, as
measured by enhancement of fibroids on gadolinium-enhanced MRI and survey
responses on modified UFS-QOL survey, among the three embolic agents: PVA, SPVA
and GM. This study is clinically relevant because there are few studies in the literature
comparing clinical outcomes among embolic agents. The practical benefit is that
physicians will use this information when deciding on which embolic agent to use for
uterine artery embolization to treat symptomatic uterine leiomyomata.
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Materials and Methods
We began our study after obtaining approval from the human investigation
committee and ensuring adherence to Health Information Portability and Accountability
Act (HIPAA) compliance. A total of 247 women who underwent UAE at our institution
were contacted by mail to complete a post-UAE survey. These patients underwent
embolization at a single institution from January 1999 to November 2004.
Inclusion criteria consisted of pre-menopausal women ages 30-55 years of age with
symptomatic leiomyomas, with or without adenomyosis; completion of the survey, either
by telephone or mail; treatment with UAE at our institution with a single embolic agent
(PVA, SPVA, or GM), baseline gadolinium-enhanced magnetic resonance (MR) imaging
examination as well as post-UAE gadolinium-enhanced MRI at our institution
approximately 6 months after the UAE. Patients with diagnosis or suspicion of diagnosis
of leiomyosarcoma were excluded from the study.

Uterine Artery Embolization Procedure
Bilateral UAE was performed by an experienced interventional radiologist in each
case. Arterial access was obtained at the right femoral artery. In order to minimize
technical failures due to collateral blood supply to fibroids, pelvic aortography using an
Omniflush Catheter (AngioDynamics, Queensbury, NY) from the level of renal arteries
was performed to evaluate for the presence of collateral blood supply to the fibroids (44).
Selective catheterization of each of the uterine arteries was then performed with a 5-F
catheter (Cook Medical Inc., Bloomington, IN), followed by insertion of a 3-F
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microcatheter (Renegade Hi-Flow; Target Therapeutics/Boston Scientific, Natick, MA)
for selective embolization of the uterine arteries.
Preparation of embolic materials varied according to product specifications. PVA
particles and SPVA particles were mixed with 6-7 mL of normal saline and 6-7 mL of IV
Contrast (various manufacturers). GM spheres were mixed with 10 mL of IV contrast to
obtain a 50% concentration of contrast in the syringe. The end point of embolization
varied among the three embolic agents according to the standard at the time of
embolization. Slow flow with near stasis in the ascending uterine artery was the end
point for the GM. Complete stasis was the end point for the PVA and SPVA. Embolic
sizes used were 500-700 and 700-900 Microns for both GM and Contour SE, while we
used particles 300-500 Microns for PVA. The choice of embolic agent used was left to
the discretion of the interventional radiologist performing the procedure.
Following embolization of both uterine arteries, pelvic aortography was repeated
from the level of the renal arteries for evaluation of perfusion of the uterine arteries as
well as evaluation for any new collateral blood supply to the uterus. In some cases,
ovarian artery collateral flow was observed, and the ovarian arteries were embolized
during the procedure.
During the procedure, patients received intravenous fentanyl and midazolam for
analgesia and sedation while a nurse monitored the patient. Ciprofloxacin was given
prior to the procedure. Patients also received IV ketorolac prior to the completion of the
procedure for additional analgesia.
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Post-Procedure Care
Immediately following the procedure, patients began using a patient-controlled
analgesia (PCA) pump, which provided morphine in the majority of patients. Seldomly,
patients would require alternate medication, such as Dilaudid (Abbott Laboratories,
Abbot Park, Illinois). These alternatives were implemented when the patient had a
known allergic reaction to morphine, or a patient had inadequate pain control with
morphine. Antiemetic drugs were used routinely during patient stay. Patients were
discharged the next morning, and were provided with oral ketorolac, oxycodone/
acetaminophen, and antiemetic medications. Patients were followed in the interventional
radiology clinic 1, 3 and 6 months after the procedure.

MRI Protocol
Patients underwent gadolinium-enhanced MR imaging before and approximately
6-months after UAE for evaluation of fibroids. Imaging was performed using a 1.5 T
Signa scanner (GE Signa, Milwaukee, WI). Sequences obtained were a localizer, fatsuppressed sagittal fast spin-echo scans (TR 6200/TE 104), coronal fast spin-echo scans
(TR 3900/TE 103), axial T1 weighted gradient echo scans (TR 180/TE 2.3, 4.8), and
coronal 3D gradient echo (TR 5.9/1.2/40) pre and post IV gadolinium administration
(0.1mmol/kg). A timing bolus was used to obtain the arterial phase. Three post contrastenhanced scans were obtained during the arterial phase, then at 60, and 120 seconds after
gadolinium administration. Subtraction images of the pre and post gadolinium scans
were subsequently performed. The field of view varied from 20 to 28cm and the matrix
was 256x256.
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Images were evaluated for uterine volume and myoma enhancement, readily
discerned on the subtraction images. The volume of the uterus was determined by the
attending radiologist dictating the case using the formula for the volume of a prolate
ellipse (transverse x axial x cranio-caudal x 0.5233) (45). On the post-UAE MRI scans,
an enhancement score (0%, 25%, 50%, 75%, or 100%) was assigned based on visual
estimate of percentage volume of all fibroids showing residual enhancement in each
patient. Baseline MRI was evaluated before the post-UAE MRI when determining
enhancement percentages in the event that there were fibroids that were already partially
infracted before UAE, and/or to identify fibroids that may have disappeared post-UAE
because they were sloughed (e.g. submucosal fibroids). A score of 0% meant complete
infarction of all fibroids, and 100% meant complete enhancement of all fibroids. Both
baseline and post-UAE MRI were assigned enhancement scores. MRI studies were
reviewed by Jorge Gálvez, with assistance from Shirley M. McCarthy MD, PhD, and
Jeffrey Weinreb MD for assignment of enhancement scores. The studies were read using
a Synapse (PACS) workstation (FUJIFILM Medical Systems USA, Stamford, CT).

Survey Design
Clinical follow-up consisted of completion of a modified UFS-QOL survey which
inquired about change of symptoms, symptom recurrence, additional interventions or
treatments, and satisfaction with outcome (46, 47). Scaling of symptoms consisted of 9
options (never had this symptom; new symptom since UAE; much worse; slightly worse;
unchanged; slightly better; much better; completely resolved; initially improved but then
worsened). The survey was modified by Jorge Gálvez in consultation with Michael G
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Tal, MD, and Elizabeth Kagan Arleo, MD, to inquire about symptom recurrence, as well
as any therapies for fibroid-related symptoms the patient may have undergone before or
after the UAE.
Each patient’s survey was evaluated individually to assess whether a given
symptom had improved, remained the same, or worsened since the UAE. Patients were
sorted into 4 categories: improvement of symptoms, no change, deterioration of
symptoms, and initial improvement followed by deterioration of symptoms. The survey
was mailed to patients on November 2004. Patients who did not respond within 2 months
were contacted by telephone by Jorge Gálvez to complete the survey.

Data Collection
Survey, MRI and UAE data was compiled in a database created by Jorge Gálvez
with Microsoft Access 2003 (Microsoft Corporation, Redmond, WA). Data
confidentiality was maintained according to HIPAA standards, using anonymous patient
ID numbers, with the identification key stored separate from the database. Initial UAE
and MRI data was obtained through chart-review conducted by Jorge Gálvez using
IDXrad (IDX Systems, Burlington, VT).

Baseline Data
The demographic characteristics, as well as treatments for fibroid-related
symptoms before or after undergoing UAE are outlined in Table 1. A total of 54 women
completed the survey, and the mean patient age was 45 years for the SPVA and GM
groups, and 49 years for the PVA group. The majority of the women treated were
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Caucasian, and approximately 50% had not sought therapies for fibroid related symptoms
prior to the UAE. A total of seven (29%) of the women embolized with PVA sought
additional therapy, two (8%) sought hysterectomy, one (5%) sought a myomectomy and
two (8%) sought a repeat UAE. Of the women embolized with SPVA, a total of six
(32%) sought additional therapy, five of which chose a repeat UAE. Lastly, of the
women embolized with GM, a total of six (55%) sought additional therapy following
UAE, including three (27%) who sought dilatation and curettage while one (9%) sought a
hysterectomy.
The fibroid-related symptoms that the women reported on the surveys occurred at
similar rates across the three embolic agents. The mean use of sanitary napkins during
the heaviest day of bleeding ranged from 6-11 sanitary napkins on the heaviest day of
flow, while the number of tampons ranged from 7-10 per day among the three embolic
agents. About half of the women in both the PVA (54%) and SPVA (44%) groups
reported that bleeding lasted more than 7 days during their menstrual cycle, in contrast to
100% of the women in the GM group.

Statistical Analysis
Data was analyzed with the use of SAS for Windows 9.1 (SAS Institute Inc, Cary,
NC) with assistance from Daniel Zelterman, PhD. Analysis was limited to comparison of
the two groups in terms of baseline and follow-up imaging outcomes, and symptoms at
time of completion of the survey. All P values reflect the result of 2-tailed fisher’s exact
tests (a = 0.05).
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Results
MRI Analysis
A total of 101 women underwent UAE with one of the three embolic agents and
had complete pre- and post-embolization MR imaging follow-up. In this group, the mean
uterine volume for patients embolized with PVA was 656 cc (± 440 cc), for SPVA it was
802 cc (± 663 cc) and for GM it was 757 cc (± 680 cc) as measured on the pre-UAE MRI
study (Table 2). A total of 24 of 59 (41%) women in the PVA group, 18 of 24 (75%)
women in the SPVA group, and 4 of 18 (22%) women in the GM group showed residual
enhancement in some or all fibroids. The PVA group had 35 (59%) women with 0%
enhancement, 21 (36%) women with partial enhancement (25-75%), and three (5%)
women with 100% enhancement of fibroids (Figure 1). The SPVA group had six (25%)
women with 0% enhancement, 16 (67%) women with partial enhancement (25-75%), and
two (8%) women with 100% enhancement (Figure 2). The GM group had 14 (78%)
women with 0% enhancement, four (22%) women with partial enhancement (25-75%),
and no (0%) women with 100% enhancement (Figure 3). When comparing embolic agent
in pairs using 2-tail Fisher’s exact test, the GM-PVA group resulted with p=0.1756, the
PVA-SPVA group resulted with p=0.0072 and the SPVA-GM group resulted with
p=0.0015 (Figure 4).
A total of four (3.9%) women underwent unilateral UAE due to absence of an
angiographically visible right or left uterine artery. Three of these women (17% of GM
patients) underwent UAE with GM, and one with PVA (1.7% of PVA patients). Only
one patient embolized with GM showed residual enhancement on post-UAE MRI. A
total of two (2%) women underwent unilateral ovarian artery embolization at the time of
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the UAE for an observed enlarged ovarian artery. Both of these women were embolized
with SPVA (8% of PVA patients), and one of them showed residual enhancement on
post-UAE MRI.

Survey Results
A total of 54 patients completed the survey by telephone or mail. Of these, 24
(44%) had been embolized with PVA, 19 (35%) with SPVA, and 11 (20%) with GM,
Seventeen (31%) patients were categorized with recurrent or persistent symptoms
following the UAE according to the survey data. Of these 17 patients, seven (29%) were
embolized with PVA, seven (37%) with SPVA, and three (27%) with GM.
The severity of bleeding symptoms, characterized by women reporting bleeding
during the menstrual cycle lasting more than 7 days decreased from 44%-100% before
therapy with UAE to 4-13% following UAE according to our surveys. Additionally, the
number of sanitary napkins or tampons used decreased by approximately 50%
(Table 3).
There were only two patients with coexisting adenomyosis who reported
recurrence of symptoms after UAE. The symptoms listed as worsening were vaginal
bleeding and pelvic pain for one patient, and abdominal distension for the other. Both of
these patients underwent UAE with PVA. (We did not receive surveys from a total of 17
women with coexisting adenomyosis who underwent UAE. Of these, 1 underwent UAE
with GM, 4 with SPVA, and 12 with PVA. See Table 4).
Of the four patients that underwent unilateral UAE (three were embolized with
GM and one with PVA), none of them reported worsening or recurrent fibroid-related
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symptoms on the surveys. Two women underwent ovarian artery embolization at the
time of the UAE for a single enlarged ovarian artery (both embolized with SPVA). One
of the patients reported initial improvement of abdominal distension followed by
worsening of this symptom while the other remains symptom-free (Table 5). While more
than half of the women in each group sought no additional therapy following UAE, there
was a number of women who sought further therapies, ranging from medical (e.g. antiinflammatory medications) to more invasive alternatives (e.g. repeat UAE,
hysterectomy), at some point after the UAE procedure.
The length of time from post-UAE MRI to completion of survey by patients,
whether by telephone or mail, varied among the three embolic agents. Patients
embolized with PVA had the longest intervals between MRI and survey completion at
34.2 months (SD ± 16.3 months), while the interval for SPVA was 3.0 months (± 4.0
months) and GM was 10.7 months (± 9.5) months (Table G).
Nearly all patients (84%) reported being satisfied with the procedure, with a total
of 57% being greatly satisfied among all embolic groups. Over 90% of patients would
recommend the procedure to a friend, and more than 80% would be willing to undergo a
repeat UAE if the fibroid-related symptoms recurred (Figure 5).

Correlation of MR imaging with clinical follow-up
Within the group of 54 patients with MR and survey data, the PVA group had
seven (29%) women with recurrent symptoms and 13 (54%) with residual enhancement,
of which five (21%) coincided with both recurrent symptoms and enhancement on
follow-up MR imaging. The SPVA group had seven (37%) women with recurrent
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symptoms and 12 (63%) with residual enhancement, of which seven (37%) coincided
with both recurrent symptoms and enhancement on follow-up MR imaging. The GM
group had three (27%) women with recurrent symptoms and three (27%) with residual
enhancement, of which two (18%) coincided with both recurrent symptoms and
enhancement on follow-up MR imaging (Table 7).
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“Even in instances in which uterine volume decreases and the dominant fibroid
shrinks, recurrence can be predicted when infarction of substantial fibroids is not
achieved.”
James B. Spies (43)

Discussion
We designed our study as a retrospective review of patients treated with UAE for
symptomatic fibroids. We prospectively reviewed the pre-UAE and post-UAE MRI
images for residual enhancement, and prospectively conducted a survey of patients to
assess improvement of fibroid-related symptoms. We were interested in evaluating the
symptomatic and imaging outcomes among three embolic agents routinely used at our
institution between 1999 and 2005. In a previous study, Pelages et al showed that
incompletely infarcted fibroids are likely to continue to grow after embolization, and thus
are more likely to cause recurrent symptoms in the future (42). Similarly, we used
gadolinium-enhanced MR imaging to classify the degree of perfusion of the fibroids
because we believe that contrast enhanced MR imaging is the best way to adequately
evaluate fibroid perfusion after fibroid ablative therapy such as UAE. Other techniques
such as ultrasound or non-contrast MRI would not detect the perfusion of the fibroids,
thus are not adequate for the purposes of this study.
In our study, statistically significant differences in recurrence of residual
enhancement on follow-up MR imaging of 101 patients were found between SPVA and
PVA, as well as SPVA and GM, but not between PVA and GM. Patients embolized with
SPVA have a higher risk of having residual enhancement on follow-up MR imaging than

22

those embolized with PVA or GM. This is particularly important because of the
associated risk of developing recurrent fibroid-related symptoms with incomplete
infarction of fibroids after UAE as detected by gadolinium enhanced MR imaging (41,
42). It is likely, that if follow up of the SPVA patients were longer, recurrence of
symptoms would have occurred in larger number of patients. Embolic agents available
for UAE have different properties, which show statistically significant differences in
recurrence of enhancement on follow-up MR imaging.
It is conceivable that the differences in residual enhancement on patients
embolized with SPVA could be due to a systematic error in our study. However, the
endpoint used was the same endpoint that had been established for PVA, and all
interventional radiologists performing the UAE had experience with this endpoint using
all three embolic agents. We also attempted to minimize false angiographic endpoints by
performing post-UAE aortography to evaluate perfusion of fibroids by uterine arteries or
by collateral ovarian arteries. The size of the embolic agents used was 500-700 Microns
for SPVA and GM, with increase to 700-900 Microns in some patients, and 355-500
Microns for PVA with increase to 500-755 Microns in some patients. Only a small
number of patients were embolized with two different sizes of a single embolic agent.
The MRI findings prior to the procedure of patients across the three embolic agent
groups were comparable, although the uterine volume was somewhat larger for patients
embolized with SPVA and GM than it was with PVA, yet this difference was not
statistically significant. Patients with larger fibroid burden became eligible for the
procedure as new embolic agents became available and the procedure was more widely
accepted by patients and clinicians.
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We used gadolinium-enhanced MR imaging to obtain qualitative estimates of the
percent of enhancement of all fibroids. This is different than previous studies, which
measure the enhancement of the dominant leiomyoma (41, 42, 48, 49). Recent studies
have taken into consideration the enhancement properties of all fibroids as a means of
assessing clinical outcomes for UAE (33, 37). We felt that it was important to consider
the perfusion of all fibroids, rather than only the dominant fibroid, to thoroughly
determine whether fibroids are at higher risk of recurring after UAE. We agree with
Spies et al. (37) that had we used ultrasonography or non-contrast MR imaging, we
would not have detected a difference among the three embolic agents. Our method may
be responsible for the relative high frequency of incomplete infarction across all embolic
agents considered in our study.
In our study, we took the necessary steps to reduce the technical causes of failure
to a minimum (43). Microcatheters were used to reduce spasm of the uterine arteries, and
thus preventing a false angiographic endpoint. Embolization endpoints used were the
standard of care at the time of the UAE. Although we included four women who
underwent unilateral UAE due to the absence of angiographically visible bilateral uterine
arteries, none of these women were embolized with SPVA.
The embolization techniques used varied according to the standards for each
embolic agent. The endpoint for patients undergoing UAE with spherical or nonspherical
PVA was near-stasis. Alternatively, the endpoint for patients undergoing UAE with GM
was sluggish-flow, according to the technique described by Spies et al (34).
We performed abdominal aortography before and after UAE to evaluate for
enlarged ovarian arteries, which are a known source of collateral flow to the fibroids (44).
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We feel that it is important to minimize the cause of technical failures for this procedure,
particularly when evaluating the effectiveness of different embolic agents. The question
of aortography use in routine practice is beyond the scope of this study.
One of the limitations of our study was that the selection of embolic agent for
each embolization procedure was non-randomized. There were a small number of
patients that met the inclusion criteria, which may have affected the results of other
outcome measures. We also did not have complete baseline information to compare the
fibroid-related symptoms before and after the treatment, thus resulting in potential for
recall bias.
Another limitation was that the completion of the survey took place at a separate
time from the post-UAE. We, therefore, have no imaging data to exactly correlate with
the symptomatic status of the patients as portrayed by their survey answers. The most
recent patients included in the study underwent embolization with SPVA and GM,
accounting for a shorter follow-up interval for these patients compared to the interval for
the PVA patients. Lastly, the patients were embolized by one of three experienced
interventional radiologists, who may have variations in technique.
The correlation between symptom recurrence and MR enhancement recurrence
after UAE does not show statistically significant differences between the three embolic
agents with the current sample of 54 patients. Patients with residual enhancement on
post-UAE MRI may not have developed symptoms at the time the survey was completed.
On the other hand, the patients whose survey responses show worsening or recurrence of
symptoms while the MRI showed no residual enhancement can be explained by the time
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between acquisition of the MRI sequences and the completion of the survey. In some
cases, the patients returned the survey up to 4 years after the UAE.
We individually evaluated every survey for signs of symptom recurrence. We did
not have baseline, pre-UAE surveys to compare, thus we relied on patient’s ability to
remember their symptoms before the embolization and compare them to their present
state. Furthermore, it was challenging to compare the surveys across the three groups
because the time lapsed between UAE and completion of survey varied highly among the
three groups. Interestingly, regardless of whether the patient had a successful
embolization or eventually developed recurrent symptoms and underwent further therapy
(from hysterectomy to repeat UAE), the majority of the women treated were glad to have
chosen UAE, and would opt to repeat the procedure rather than undergo a hysterectomy
if the need arose.
The failure of SPVA in our study, in accordance with the previous study by Spies
et al. (37), raises the question about the quality of evidence that we consider for products
that are introduced into practice. It is clear that both the composition of embolic agents,
as well as their size and shape are important factors that affect the way they behave once
deployed. It is important for future studies to use adequate imaging protocols to measure
the outcomes when evaluating new embolic agents prior to their use in clinical practice.
The reason for the higher incidence of residual enhancement following UAE with
SPVA can only be speculated. Indirect evidence suggests that SPVA migrates more
distally than other embolics (50). Perhaps it is compressed as it passes through the
microcatheters, and thus temporarily assumes a different shape, allowing it to travel
through smaller vessels. It is also possible that the material clumps after it is compressed
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in the microcatheter, and thus causes occlusion of a proximal vessel, resulting in a false
angiographic endpoint. At some point after the procedure is completed, the clump can
break down and migrate distally to incompletely occlude all of the fibroid vessels.
When used as described in our methods, SPVA has a substantially lower
likelihood of achieving complete infarction of uterine fibroids in comparison to GM and
PVA. However, there are currently no studies evaluating the effectiveness of different
embolization techniques with SPVA, which could produce a higher infarction rate. In
conclusion, nonetheless, it is our opinion that spherical poly-vinyl alcohol (SPVA) does
not qualify as an effective embolic agent for Uterine Artery Embolization for
symptomatic fibroids.
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Conclusions
In summary, we designed a retrospective study comparing symptom and imaging
outcomes among three embolic agents available for uterine artery embolization.
We hypothesized that there are differences in clinical outcome among the three
embolic agents: PVA, SPVA and GM. We found that there is a higher incidence of
incomplete infarction for patients who underwent UAE with SPVA as measured by
gadolinium-enhanced MRI when compared to both PVA and GM, but there is no
difference in infarction rates of fibroids between PVA and GM. We found no statistically
significant differences among clinical outcomes when grouping residual MR
enhancement and recurrent symptoms based on the questionnaire responses. However,
this could be due to the small sample of patients who completed the survey.
In conclusion, poly-vinyl alcohol spheres, when used as described in the methods
section, is not an effective embolic agent for use in uterine artery embolization for
treatment of symptomatic fibroids.
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Appendix A - Figures
Figure 1 – MRI studies before and after UAE with PVA particles.(PVA)

A

B

C

D

Pre-UAE imaging shown in (A): T2-weighted sagittal image demonstrating large fibroid,
which (B) completely enhances on sagittal gadolinium SPGR sequence (B). Follow-up
imaging approximately 10 months after UAE shows the fibroid have diminished in size
on (C) T2 sagittal-weighted image, and (D) are no longer enhancing post-gadolinium
administration.
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Figure 2 - MRI studies before and after UAE with poly-vinyl alcohol spheres (SPVA)
particles.

AA

BB

CC

DD

Pre-UAE MRI scans shown (A and B); Multiple large fibroids visible on coronal T2weighted image (A) which completely enhance with gadolinium administration (B).
Follow-up imaging at 7 months after UAE shows several fibroids on T2-weighted
coronal image (C) that continue to demonstrate complete enhancement following
gadolinium administration (D).
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Figure 3 - MRI studies before and after UAE with tris-acryl gelatin (GM) particles.

A

B

C

D

Pre-UAE imaging shows two large fibroids on T2-weighted coronal image (A) which
completely enhance post-gadolinium administration (B). Follow-up at 5 months after
UAE show some decrease in the size of fibroids on T2-weighted coronal image (C) with
no residual enhancement post-gadolinium administration (D).
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Figure 4 - Correlation of embolic
agents with post-UAE gadoliniumenhanced MRI residual
enhancement
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Statistical analysis with 2-tail Fisher’s exact test, PVA-SPVA (24, 35, 18, 6)
p=0.0072; SPVA-GM (18, 6, 4, 14) p=0.0015); PVA-GM (24, 35, 4, 14)
p=0.1756.
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Figure 5 - Patient satisfaction
results from survey data
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Summary of patient satisfaction items from survey data.
PVA
SPVA
n=24
n=19
Willingness to undergo repeat UAE for
21
15
ecurrent symptoms
(88%)
(79%)
Willing to recommend UAE for treatment
23
19
f fibroid-symptoms to friends
(96%)
(100%)

GM
n=11
11
(100%)
11
(100%)

Overall
47
(87%)
51
(94%)
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Appendix B – Tables
Table 1 – Baseline characteristics of women undergoing UAE (based on survey’s
returned)
PVA
SPVA
GM
Number of patients (n=51)
n=24
n=16
n=11
Age (years)
49 (+/45 (+/- 4.0)
45 (+/5.9)
9.1)
Ethnicity
African American 5 (21%)
7 (44%)
2 (18%)
Caucasian 17 (71%)
8 (50%)
6 (55%)
Asian
1 (4%)
0
1 (9%)
Hispanic
1 (4%)
0
0
Other
0
0
2 (18%)
Omitted
0
1 (6%)
0
Pre-UAE Therapies^
No therapy 15 (63%)
8 (50%)
5 (45%)
Medical therapy 7 (29%)
6 (38%)
5 (45%)
Dilatation & Curettage 2 (18%)
2 (12.5%)
6 (54%)
Myomectomy
1 (4%)
3 (19%)
0
Endometrial Ablation
0
0
1 (9%)
Post-UAE Therapies^
No additional therapy 18 (75%)
11 (69%)
7 (64%)
Medical Therapy
2 (8%)
1 (6%)
2 (18%)
Dilatation & Curettage
0
0
3 (27%)
Myomectomy
1 (4%)
0
0
Hysterectomy 2* (8%)
0
1** (9%)
Uterine Artery Embolization
1 (4%)
2 (13%)
0
«
Coexisting Adenomyosis
16 (27%)
7 (29%)
3 (17%)
* One hysterectomy done to treat cervical cancer, and the other to treat fibroid-related symptoms.
** Hysterectomy done to treat fibroid-related symptoms.
^ Some patients underwent multiple therapies before and after UAE, thus numbers may not reflect sample
size of 51.
«
Percentage of patients with coexisting adenomyosis calculated from total patients with MRI studies (PVA
n=59; CSE n=24; GM n=18)
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Table 2 – Mean uterine volume measured before on pre-UAE MRI studies.
Embolic Agent Mean Uterine volume
PVA
656 cc (± 440cc)
SPVA
802 cc (± 663 cc)
GM
757 cc (± 680 cc)
Measurements were obtained using the formula for volume of a prolate ellipse (transverse x craniocaudal x
sagittal x 0.5233).

Table 3 – Baseline fibroid-related symptoms from survey
PVA (n=24)
SPVA (n=16)
GM (n=11)
Bleeding longer than 7 days during menstrual cycle
Before UAE
13 (54%)
7 (44%)
11 (100%)
After UAE
1 (4%)
2 (13%)
1 (9%)
Mean number of sanitary towels used on heaviest day of bleeding during menstrual cycle
Mean (Std Dev) N Mean (Std Dev) n
Mean (Std Dev)
n
Before UAE
17
13
11
6 (± 3)
9 (± 6)
11 (± 10)
After UAE
20
12
10
1 (± 2)
6 (± 6)
4 (± 5)
Mean number of tampons used on heaviest day of bleeding during menstrual cycle
Mean (Std Dev) n
Mean (Std Dev) n
Mean (Std Dev)
n
Before UAE
13
11
6
9 (± 6)
10 (± 7)
7 (± 3)
After UAE
19
8
11
2 (± 3)
5 (± 3)
1 (± 2)
Table 4 - Patients with coexisting adenomyosis showing either complete infarction of all
fibroids on post-UAE MRI, or partial enhancement of some or all fibroids on post UAE
MRI.
PVA (n=54)
SPVA (n=24)
GM (n=18)
Incomplete Infarction
3 (6%)
3 (13%)
0 (0%)
Complete Infarction
12 (22%)
4 (17%)
3 (17%)
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Table 5 - Summary of symptom outcomes from survey data.
PVA
n=24

SPVA
n=19

GM
n=11

Deteriorating
Initially improved then worsened
No change
Improve
Never had Symptom

0
1
1
18
2

1
4
3
10
2

0
1
2
7
1

Deteriorating
Initially improved then worsened
No change
Improve
Never had Symptom

0
0
2
15
5

1
1
3
10
4

0
2
0
7
2

Deteriorating
Initially improved then worsened
No change
Improve
Never had Symptom

0
1
1
16
4

0
1
2
16
0

0
1
1
10
0

Deteriorating
Initially improved then worsened
No change
Improve
Never had Symptom

0
0
0
15
5

1
1
3
11
3

0
0
1
10
0

Deteriorating
Initially improved then worsened
No change
Improve
Never had Symptom

n/a
n/a
2
5
15

1
1
1
5
11

1
0
1
4
5

Abdominal Distension

Urinary Frequency

Heavy Vaginal Bleeding

Pelvic Pressure or Pain

Dyspareunia

Hot Flashes
Deteriorating
2
0
Initially improved then worsened
0
0
No change
3
1
Improve
4
0
Never had Symptom
13
17
Note that discrepancies on survey answer totals are due to patients omitting answers to
some of the questions on the survey.
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1
2
1
1
5

Table 6 – Time between post-UAE MRI and completion of survey
Months
SPVA
3.0 (± 4.0)
PVA
34.2 (± 16.3)
GM
10.7 (± 9.5)
Mean time (months) elapsing between post-UAE MRI study and completion of symptom
questionnaire. The mean time difference between follow-up MR imaging and completion
of survey was 34.2 months (+/- 16.3 months) for PVA, 3 months (+/- 4 months) for
SPVA, and 10.7 months (+/- 9.5 months) for GM.

Table 7 – Correlation of follow-up MRI residual enhancement and recurrent symptoms
Agent
PVA (n=25)
SPVA (n=16)
GM (n=10)

Residual Enhancement (25%-100%)
Recurrent Symptoms Symptom-Free
5 (20%)
7* (28%)
7 (44%)
5* (31%)
2 (20%)
1* (10%)

No Residual Enhancement (0%)
Recurrent Symptoms Symptom-Free
2** (8%)
11 (44%)
0**
4 (25%)
1*** (10%)
6 (60%)

* Patients may not have developed recurrent symptoms yet despite having residual
enhancement on post-UAE MRI.
** These patients were embolized with PVA, and follow-up MRI was done at six and 10
months after UAE, while surveys were returned at 5.4 and 2.3 years after UAE
respectively. *** This patient was embolized with GM, who had the follow-up MRI at
2.2 months after UAE and returned the questionnaire at 8.5 months after UAE.
**, *** None of these patients had evidence of adenomyosis, enlarged ovarian arteries, or
spasm during embolization procedure.
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Instructions:
These questions ask about symptoms experienced by women who have uterine fibroids,
as well as about treatments for fibroids, pregnancy, and sexual function. Please answer
them as honestly as possible. There are no right or wrong answers. Your responses will
be kept completely confidential.
UAE = Uterine Artery Embolization (Also known as Uterine Fibroid Embolization)
1. Last Name

First Name

2. Ethnicity (circle one)
a. Caucasian
b. African American c. Asian
3. Today’s Date

Date of Birth

d. Other (specify):

4. Date of your uterine artery embolization (UAE) procedure?

5. What therapies did you have to treat fibroids before your UAE? (circle all that apply)
a. I did not have any therapies to treat fibroids before UAE
b. Medical therapy with (circle all that apply):
i. Birth control pills
ii. Anti-Inflammatory (such as Motrin, Alleve, Advil, Aspirin, Ibuprofen)
iii. Lupron (also known as Leuprolide)
iv. Other (circle one): Danazol / Gestrione / Raloxifene / Mifepristone (RU-486)
c. Myomectomy (surgical removal of fibroids without hysterectomy)
d. Endometrial ablation (removing the uterine lining using laser or electrosurgery)
e. D&C (scraping and removing the uterine lining using a curette inserted through the
vagina)
f. Other (specify): _____________________________________________________
6. What therapies have you had after your UAE for recurrent or continuing fibroid-related symptoms,
or due to a complication of UAE? (circle all that apply and specify the reason why)
a. I have not had any additional therapies after UAE
b. Repeat UAE: reason why - _____________________________________________
c. Hysterectomy (surgical removal of uterus) – reason _________________________
d. Myomectomy - ______________________________________________________
e. Medical therapy with (circle all that apply) reason __________________________
a. Birth control pills
b. Anti-inflammatory (such as Motrin, Alleve, Advil, Aspirin, Ibuprofen)
c. Lupron (also known as Leuprolide)
d. Other (circle one) Danazol / Gestrione/ Raloxifene / Mifepristone RU-486
f. endometrial ablation – reason: __________________________________________
g. D&C – reason: ______________________________________________________
h. Other (specify reason): ______________________________________________
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II. Fibroid-related symptoms
1. Before UAE, did your menstrual periods last longer than 7 days?

YES

NO

2. Before uterine artery embolization (UAE), approximately how many pads and/or tampons did you use on the
heaviest day of bleeding during your menstrual period? (fill in the blanks)
Number of pads =
Number of tampons =

3. When did your menstrual periods resume after UAE (circle one)
e. My menstrual periods have not resumed after UAE
e. Within 9 months after UAE
When1did
yourafter
menstrual
f. 3.
Within
month
UAE periods resume after UAE (circle
f. one)
Within 12 months after UAE
a. My
menstrual
e. Within 9____
months
after UAE
g. Within
3 months
afterperiods
UAE have not resumed after UAE g. Other:
months
b. Within
1 month
after UAE
f.after
Within
12 months after UAE
h. Within
6 months
after UAE
UAE.
c. Within 3 months after UAE
g. Other: Within ____ months
4. If your menstrual
haveafter
resumed
d. Withinperiods
6 months
UAE after UAE, is your menstrual cycle regular?
after YES
UAE. NO
5. Now (during the past 3 months), do your menstrual periods last longer than 7 days?
a. YES: this began approximately ____ months after UAE
b. NO
6. Now (during the past 3 months), approximately how many pads and/or tampons do you use on the
heaviest day of bleeding during your menstrual period? (circle one)
a. Number of pads = ______
Number of tampons = ______
b. I have not had menstrual periods during the past three months
7. At any time after UAE, have you had a recurrence of any fibroid-related symptoms?
a. YES : the following symptoms have recurred: ____________________________________ b. NO
8. How would you rate the following fibroid-related symptoms now (during the past 3 months) in
comparison to before you underwent UAE? (for each symptom, check one box)
Never
had this
symptom

New
symptom
since UAE

Much
worse

Slightly
worse

No
change

Slightly
improved

Much
improved

Completely
resolved

Initially
improved but
then got worse

Abdominal
distension/ bulk
Urinary
frequency/urgency
Heavy vaginal
bleeding
Pelvic pressure /
pain
Painful sexual
intercourse
Hot flashes

9. If your fibroid-related symptom(s) improved after UAE, how long did it take for them to improve (for
each symptom, check one box).
Did not have
symptom
before UAE
Abdominal Distension/bulk
Urinary frequency/urgency
Heavy vaginal bleeding
Pelvic Pressure/pain
Painful sexual intercourse
Hot flashes

Improved
within 1
month

Improved
within 6
months

Improved
within 12
months

Improved
within 24
months

Initially
improved but
then got worse
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Did not
improve at
all

1. Before UAE, did you think you might want to try to get pregnant after UAE?

Yes

No

2. Before UAE, how many times had you been pregnant, including miscarriages and
abortions/surgical terminations of pregnancy (fill in the blanks with a number)
a. Number of pregnancies before UAE = _____
b. Number of miscarriages before UAE = _____
c. Number of abortions/surgical terminations before UAE = ____
3. After UAE, have you tried to get pregnant? (circle one)

Yes

No

4. After UAE, have you engaged in heterosexual intercourse without contraceptive use? (circle one)
Yes No
5. After UAE, how many times have you been pregnant, including miscarriages and
abortions/surgical terminations of pregnancy? (fill in the blanks with a number)
a. Number of pregnancies after UAE = ___
b. Number of miscarriages after UAE = ___
(i) how far along in the pregnancy were you when the miscarriage occurred? ___
(ii) how many months after UAE did the miscarriage occur? ___
c. Number of abortions/surgical terminations after UAE? ___
6. If you have been pregnant after UAE, please answer the following questions about each baby you
have delivered. If you have not been pregnant after UAE, please skip this question.
a. What was your delivery date? (m/d/y)? _________
b. What was the original due date of your pregnancy? (m/d/y) _________
c. How much did your baby weigh? (lbs and ozs) _________
d. How was your baby delivered? (circle one)
(i) Vaginal (including forceps or vacuum)
(ii) Planned C-section
(iii) C-section after labor started
e. Baby’s position right before delivery: (circle one)
(i) head first
(ii) feet first
(iii) sideways
(iv) I don’t know
f. Did you have any complications? (circle as many as apply)
(i) no complications
(ii) uterine rupture
(iii) retained placenta
g. Other (please specify) ____________________________________
7. Were you ever diagnosed with any of the following conditions? (circle all that apply and specify
appropriate date of diagnosis)
a. Adenomyosis, diagnosed _____________________
b. Endometriosis, diagnosed _____________________
c. Pelvic inflammatory disease, diagnosed __________________
d. Infertility (specify) _______________; diagnosed _______________
e. I have not been diagnosed with any of the above conditions.
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IV. Sexual Function Questions
1. How would you rate the following aspects of your sexual function now (during the past
three months) in comparison to before UAE? (for each aspect of sexual function, check
one box).
In answering this section, the following definitions apply:
• Sexual desire or interest: wanting to have a sexual experience, feeling receptive to
a partner’s sexual initiation, and thinking or fantasizing about having sex
• Sexual arousal: a feeling that includes both mental as well as physical aspects of
sexual excitement, including feelings of warmth or tingling in the genitals,
lubrication/wetness, or muscle contractions
Much
worse

Slightly
worse

Unchanged Slightly
improved

Much
improved

Initially
improved
but then
got worse

Sexual desire or
interest
Sexual arousal
Orgasm/climax
(frequency/intensity)
Discomfort or pain
during sexual
intercourse
Overall satisfaction
with sexual function
V. Treatment of Satisfaction Questions
1. Would you be willing to undergo another UAE if necessary to treat recurrent or continuing
fibroid-related symptoms? (circle one)
YES NO
2. Would you recommend UAE to other women for treatment of symptomatic fibroids (circle
one) YES NO
3. Overall satisfaction rating with UAE (circle one)
a. Greatly Dissatisfied
d. Midlly satisfied
b. Moderately Dissatisfied e. Moderately Satisfied
c. Mildly Dissatisfied
f. Greatly Sastisfied
Thank you for completing this questionnaire! Please return it in the pre-addressed, prestamped envelope. If the envelope has been misplaced, please return the questionnaire to
the physician(s) who performed your uterine artery embolization (UAE)
Michael Tal MD, Jeffrey Pollak MD, or Robert White MD
Yale-New Haven Hospital
Department of Diagnostic Radiology
20 York St 2-213 SP
New Haven, CT. 06520-8042
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Appendix D – Presentations
Galvez J, McCarthy S, Tal M, et al. Comparison of MRI and symptom outcomes of
uterine artery embolization for uterine leiomyoma using tris-acryl gelatin
microspheres, poly-vinyl alcohol spheres and poly-vinyl alcohol particles.
Radiology Society of North America 2005.
Galvez J, Pollak J, Tal M. Repeat uterine artery embolization after recurrence of
symptoms. Radiology Society of North America 2005.
Galvez J, McCarthy S, Pollak J, Tal M. MRI Determined Tissue Perfusion Of
Ovaries, Myometrium And Fibroids Before And 6 Months After UAE.
Society of Interventional Radiology, March 2005.
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Appendix E: Press-Releases
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